All Stories

  1. Can Malaria Induce Loss of Vaccine Immunity?
  2. Induction of Salivary IgA and IgG Responses by Parenteral PPV23 Vaccination in Older Adults
  3. Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea
  4. Primary human nasal, nasopharyngeal, and bronchial epithelia show distinct immune responses to various pathogens
  5. Impact of host factors and invasive meningococci on bacterial adhesion, proliferation, primary nasal epithelial barrier function, and immune response
  6. Decay Rates of Maternal Tetanus, Diphtheria, and Pertussis Antibody Levels in Early and Moderate-to-Late Preterm and Term Infants at Birth and at Two Months
  7. Contact behaviour before, during and after the COVID-19 pandemic in the Netherlands: evidence from contact surveys, 2016 to 2017 and 2020 to 2023
  8. SARS‐CoV‐2 Seroprevalence Trends in the Netherlands in the Variant of Concern Era: Input for Future Response
  9. Exploring host-commensal-pathogen dynamics in cell line and organotypic human intestinal epithelial models
  10. The impact of SARS-CoV-2 on fatigue and quality of life in the early phase of the pandemic: prevalence of post COVID-19 condition among unvaccinated individuals in a Dutch population-based serosurveillance cohort
  11. Contact behaviour before, during and after the COVID-19 pandemic in the Netherlands: evidence from contact surveys in 2016-2017 and 2020-2023
  12. Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trial
  13. Prevalence of human respiratory pathogens and associated mucosal cytokine levels in young children and adults: a cross-sectional observational study in the Netherlands during the winter of 2012/2013
  14. Ecological interactions between host, commensal and pathogenic bacteria in models for the intestinal epithelium
  15. COVID-19 vaccination-induced antibody responses and waning by age and comorbidity status in a large population-based prospective cohort study
  16. Association between common adverse events after COVID-19 vaccination and anti-SARS-CoV-2 antibody concentrations in a population-based prospective cohort study in the Netherlands
  17. Effects of COVID-19 vaccination and previous infection on Omicron SARS-CoV-2 infection and relation with serology
  18. Factors associated with long-term antibody response after COVID-19 vaccination in patients treated with systemic treatment for solid tumors
  19. Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from July 12, 2021 to June 6, 2022: A prospective cohort study
  20. Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study
  21. Age-specific severity of SARS-CoV-2 in February 2020 – June 2021 in the Netherlands
  22. Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection in the Netherlands, September to December 2022
  23. The effect of previous SARS-CoV-2 infection and COVID-19 vaccination on SARS-CoV-2 Omicron infection and relation with serological response – a prospective cohort study
  24. Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from 12 July 2021 to 6 June 2022: a prospective cohort study
  25. Safety and Immunogenicity of Intradermal Fractional Dose Administration of the mRNA-1273 Vaccine: A Proof-of-Concept Study
  26. Reduced Antibody Acquisition with Increasing Age following Vaccination with BNT162b2: Results from Two Longitudinal Cohort Studies in The Netherlands
  27. Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome
  28. Design and baseline description of an observational population-based cohort study on COVID-19 vaccine effectiveness in the Netherlands - The VAccine Study COvid-19 (VASCO)
  29. Three-dose mRNA-1273 vaccination schedule: sufficient antibody response in majority of immunocompromised hematology patients
  30. Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients
  31. Chemokine profiling in children and adults with symptomatic and asymptomatic respiratory viral infections
  32. Circulation of Bordetella pertussis in the Caribbean Netherlands: a population-based seroepidemiological study
  33. Children and adults with mild COVID-19 symptoms develop memory T cell immunity to SARS-CoV-2
  34. Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy
  35. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees
  36. Asthma-Associated Long TSLP Inhibits the Production of IgA
  37. Persistence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 in Relation to Symptoms in a Nationwide Prospective Study
  38. Berberine and Obatoclax Inhibit SARS-Cov-2 Replication in Primary Human Nasal Epithelial Cells In Vitro
  39. Berberine and obatoclax inhibit SARS-CoV-2 replication in primary human nasal epithelial cells in vitro
  40. Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave
  41. Trimeric SARS-CoV-2 Spike Proteins Produced from CHO Cells in Bioreactors Are High-Quality Antigens
  42. Antibody Responses to Respiratory Syncytial Virus: A Cross-Sectional Serosurveillance Study in the Dutch Population Focusing on Infants Younger Than 2 Years
  43. SARS-CoV-2–Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence
  44. SARS-CoV-2-specific antibody detection for sero-epidemiology: a multiplex analysis approach accounting for accurate seroprevalence
  45. Inhibition of IgA production by asthma-associated long TSLP
  46. Immune surveillance for vaccine-preventable diseases
  47. Bordetella pertussis Induces Interferon Gamma Production by Natural Killer Cells, Resulting in Chemoattraction by Respiratory Epithelial Cells
  48. The development of a bead-based multiplex immunoassay for the detection of IgG antibodies to CMV and EBV
  49. BAFF augments IgA2 and IL‐10 production by TLR7/8 stimulated total peripheral blood B cells
  50. Oxidative Stress Resulting From Helicobacter pylori Infection Contributes to Gastric Carcinogenesis
  51. Intestinal immune maturation is accompanied by temporal changes in the composition of the microbiota
  52. An alternative inhibition method for determining cross-reactive allergens
  53. 5 Regulation of Rac1 and Reactive Oxygen Species Production in Response to Helicobacter pylori Infection of Gastric Epithelium
  54. 973 Human Intestinal Epithelial Host Defense Against Pathogenic Bacterial Infections is Regulated by AP Endonuclease 1 (APE1/Ref-1)
  55. House dust mite-specific IgA2 is associated with protection against eczema in allergic patients
  56. Regulation of Rac1 and Reactive Oxygen Species Production in Response to Infection of Gastrointestinal Epithelia
  57. Specificity and Effector Functions of Human RSV-Specific IgG from Bovine Milk
  58. Ontogeny of the avian intestinal immunoglobulin repertoire: Modification in CDR3 length and conserved VH-pseudogene usage
  59. The Mucosal Factors Retinoic Acid and TGF-β1 Induce Phenotypically and Functionally Distinct Dendritic Cell Types
  60. Modulation of Human Immune Responses by Bovine Interleukin-10
  61. Successive immunoglobulin and cytokine expression in the small intestine of juvenile chicken
  62. 4 Wat gebeurt er bij een allergie?
  63. Relevance of IgA in allergy: regulation by mucosal factors